Apyx Holds $59.5M 2026 Revenue Target as AYON Adds FDA-Cleared Liposuction

Apyx's guidance says the base business is holding while AYON adds a new use case

Apyx's message is straightforward: the core business is still growing, and the new AYON capability is being added to an operating base that already has momentum. The company reported Q2 revenue of $13.9 million versus $11.4 million a year earlier, while Surgical Aesthetics revenue rose to $12.4 million from $9.7 million in Q2 2025. That gives the new feature a stronger starting point than a stalled or flat platform would.

The product change is also clear. The FDA now allows power liposuction, which management describes as a way to reduce surgeon effort and operating room time. Apyx has also begun a limited commercial launch with initial commercial shipments in June 2026. That makes this an early operating test, not a full-scale ramp.

The market's hesitation is understandable. Apyx moved from a prior FY2026 range of $57.5 million to $58.5 million to a reaffirmed $59.0 million to $60.0 million outlook. The raise is modest, but it still suggests management sees room for upside if the new capability starts feeding into broader adoption over the next few quarters.

Why a second modality could increase wallet share

The key question is not whether AYON has another label line. It is whether the added capability can make the system more useful inside the operating room and drive more repeat business from the same customer base.

A unified platform can be easier to sell into existing workflows

Management says the new clearance adds power liposuction as a second advanced liposuction modality and enables multiple body contouring functions within one system. If that proves useful in practice, surgeons may be more likely to stick with one platform rather than add a competitor's device for a separate function.

That matters because Apyx does not rely on hardware sales alone. Revenue can also come from consumables and deeper use of the ecosystem. In Q2, the company posted 28% growth in the Surgical Aesthetics segment, and in the prior quarter it reported record total revenue of $19.2 million. It also said it was scaling the U.S. commercial launch of AYON to meet strong demand. So the new capability is being layered onto a business that is already moving.

More features do not automatically mean better margins

Apyx is taking a careful rollout approach. The company said it plans to refine training, utilization, and the overall customer experience before scaling commercial adoption. That is prudent, but it also means investors should not assume an immediate margin benefit.

Near term, the trade-offs are familiar for early medical-device launches:

• training and support can be labor-intensive relative to booked revenue
• pricing power may remain limited while adoption is still being proven
• service and implementation costs can stay higher until the workflow is streamlined

That is why the guidance response matters. Apyx did not raise the full-year target aggressively after the FDA clearance. That is not a negative signal by itself, but it does keep expectations grounded.

What matters most is whether the limited launch starts converting

With guidance already anchored near the $59.0 million to $60.0 million mark, the next upside has to come from operating proof rather than label excitement. The real test is whether power liposuction becomes a routine tool in the operating room or remains mainly a differentiator on paper.

Signposts that would support the thesis

Watch for evidence that the new modality is doing more than attracting curiosity:

• broader customer participation beyond the initial limited launch
• signs of repeat purchases or higher consumable use
• smoother commercial execution as training and utilization improve
• guidance that gradually reflects the added capability

If those signals appear, the current revenue range could look conservative. If they do not, the story is more likely to remain a product-expansion narrative with limited near-term earnings leverage.